NSAIDS May Limit Passage of Narcolepsy Medication Gamma Hydroxybutyric Acid to the Brain
Previous studies completed by the UB researchers found that the NSAIDs ibuprofen and ketoprofen also affected the movement of GHB in the body.
Category: Prescription Drugs
Prescription Drugs
LatestPrescription Drugs
Latest
Two Poster Presentations Include New Post-Hoc Analyses That Highlight Clinical Effectiveness of WAKIX
"The analyses include both a traditional approach to presenting efficacy data, as well as one that underscores the clinical relevance of the findings, using [number needed to treat] and effect sizes to capture overall clinical benefit."
Prescription Drugs
Latest
Why Holistic Treatments for Insomnia Are Becoming More Popular
Though many people with insomnia go into doctor’s visits expecting a drug to relieve sleeplessness, stakeholders are moving increasingly toward holistic approaches.
What We Know About Narcolepsy, Sodium Oxybate Use, Salt Intake & Cardiovascular Risk
A literature review from Stanford University looks at how the popular narcolepsy medication sodium oxybate impacts heart health.
Read More
Z-Drugs Have Similar or Greater Adverse Events in Dementia Patients as Benzos
Researchers studied the adverse events for 3,532 patients who had been prescribed Z-drugs and compared them to people with sleep disturbance who had not been prescribed sedatives and with patients who had been prescribed benzodiazepines.
Read MoreEuropean Commission Fines Teva & Cephalon for Delaying Entry of Generic Modafinil
The commission investigation has found that for several years, this “pay-for-delay” agreement eliminated Teva as a competitor and allowed Cephalon to continue charging high prices even if the main modafinil patent had long expired.
Read MoreFDA Approves HETLIOZ for Sleep Disturbances in Smith-Magenis Syndrome
Smith-Magenis Syndrome is a rare neurodevelopmental disorder, a defining feature of which is an “inverted” circadian rhythm.
Read More
Insomnia Patient Survey Offers Some Answers on Prescription Drug Use
Health Union, which creates condition-specific online patient communities, shared results from its Sleep Disorders In America survey.
Read More
Expanded WAKIX Label Could ‘Help Even More People Living with Narcolepsy’
The FDA says that Harmony Biosciences’ drug—previously approved for excessive daytime sleepiness in narcolepsy—works for cataplexy too. Harmony’s chief medical officer explains how this impacts healthcare practitioners and patients.
Read More
Xywav Phase 3 Data Published in SLEEP
Results of the double-blind, placebo-controlled, randomized-withdrawal, multicenter study were previously presented at World Sleep 2019.
Read More
WAKIX Gets Additional FDA Approval—for Cataplexy
FDA approval of WAKIX for the treatment of cataplexy in adult patients with narcolepsy is based on two randomized, controlled trials.
Read More
Drugs Aren’t Typically Tested on Women. AI Could Correct That Bias.
Though men and women can have different responses to medications—Ambien, for example, metabolizes more slowly in women, causing next-day grogginess—doctors may not know about these differences because most clinical trial data are biased toward men.
Read More
FDA Requires Label Changes for Benzos
Benzodiazepines are ‘commonly abused and misused, often together with opioid pain relievers and other medicines, alcohol, and illicit drugs.’
Read More
How Benzos Act on Receptors in the Brain
The GABAA receptor is particularly sensitive to its surrounding environment and has the ability to change conformation in different ways based on the binding of different drugs.
Read More
Xywav or Xyrem: What’s the Difference?
The FDA approved a new oxybate formulation for excessive daytime sleepiness or cataplexy in narcolepsy. Should your patients switch?
Read More
Large Study Finds Narcolepsy Drug Does Not Up Risk of Fetal Malformation
A registry study involving 2 million pregnant women shows no association between modafinil and an increased risk of malformation in babies.
Read MoreJazz Presents New Data on Xywav & Sunosi at Virtual SLEEP 2020
Highlights include presentations on Xywav, a lower sodium oxybate iindicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
Read MoreHarmony Presents New WAKIX Data at Virtual SLEEP 2020
The data include a final analysis of the Pitolisant Expanded Access Clinical Evaluation Program, two post-hoc analyses on clinically relevant outcomes from the Phase 3 clinical trials, and analyses that further characterize the cardiac safety profile of WAKIX.
Read More